| 2026-06-04 | Press release | Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establi |
| 2026-06-03 | Press release | Celularity Releases CEO Letter to Shareholders |
| 2026-06-03 | Press release | Celularity Appoints Rick Gonzalez as Chief Commercial Officer |
| 2026-04-21 | Press release | Celularity Announces Closing of Transaction with NexGel |
| 2026-03-10 | Press release | Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strateg |
| 2026-02-10 | Press release | Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses |
| 2025-12-26 | Press release | Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determ |
| 2025-12-22 | Press release | Celularity Announces Closing of Financing Transactions |
| 2025-12-18 | Press release | Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision |
| 2025-10-30 | Press release | Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care |
| 2025-10-14 | Press release | Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy o |
| 2025-08-18 | Press release | Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt |
| 2025-07-09 | Press release | Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law |
| 2025-07-01 | Press release | Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies |
| 2025-06-10 | Press release | Celularity Announces Chief Financial Officer Transition |
| 2025-06-02 | Press release | Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology |
| 2025-05-09 | Press release | Celularity Announces Full Year 2024 Operating and Financial Results |
| 2025-04-14 | Press release | Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products |
| 2025-04-07 | Press release | Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” i |
| 2025-02-25 | Press release | Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Product |
| 2025-02-24 | Press release | Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company |
| 2025-02-20 | Presentation | View Investor Deck |
| 2025-01-27 | Press release | MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs |
| 2024-12-06 | Press release | Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 |
| 2024-11-07 | Press release | Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million |
| 2024-10-23 | Press release | Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel |
| 2024-10-22 | Press release | Celularity Provides Corporate Update |
| 2024-10-16 | Press release | Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence |
| 2024-09-09 | Presentation | VIEW PDF |
| 2024-09-05 | Press release | Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference |
| 2024-08-28 | Press release | Celularity Appoints Richard J. Berman to its Board of Directors |
| 2024-07-31 | Press release | Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announc |
| 2024-06-03 | Press release | Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American |
| 2024-05-21 | Presentation | VIEW PDF |